BOI Bank Irel13.375

RNS Number:9460W
Biotrace International PLC
16 January 2006



For Immediate Release                                           16 January 2006


                           BIOTRACE INTERNATIONAL PLC
                                  ("Biotrace")

Biotrace signs global agreement with Pall Corporation to market microbiological
            air monitoring technology to the pharmaceutical industry

Biotrace International Plc, a leading manufacturer of industrial microbiology
and life science products, announced today that it has entered into an agreement
with Pall Corporation ("Pall") (NYSE: PLL) giving Pall exclusive global
marketing and distribution rights to the range of Ascotec environmental air
monitoring products for the pharmaceutical industry. As part of the worldwide
agreement, the two companies will also work together on the development of
additional innovative products for the rapid detection of contamination.
Microbiological monitoring of manufacturing processes is critical to ensuring
compliance with regulatory requirements and product safety.

Biotrace's Ascotec products are used to monitor the quality of the air and
compressed gases in the production environment. They are used wherever clean
rooms are required for manufacturing of pharmaceuticals, personal care products
and cosmetics and in other clinical environments such as hospitals to reliably
capture bacteria in the environment for subsequent monitoring. The agreement
will provide industry with the ability to access the Ascotec air monitoring
technologies to better enable them to achieve the goals of the U.S. FDA Process
Analytical Technology (PAT) initiative. The PAT initiative encourages
manufacturers to adopt new analytical technologies to better control
manufacturing processes and provide greater assurances of product safety.

Ian Johnson, Chief Executive Officer of Biotrace, said:

"This agreement is another important milestone in our strategy to develop a
broad business base in industrial microbiology. Our leading position in
proprietary microbial testing technologies coupled with Pall's strong customer
relationships worldwide in the pharmaceutical industries will greatly enhance
our presence in this attractive market. The combination of Pall's filtration
technologies and know how with our technologies and expertise in rapid
microbiology will create the next generation of fast testing solutions reducing
the 'time to result' and improving production efficiency."

Ken Frank, Corporate Vice President of Pall and President of the
BioPharmaceuticals Division, said:

"The addition of the Ascotec air sampler to our rapid microbiology platform,
including the PallchekTM monitor, gives customers around the globe access to a
proven technology that meets the most stringent clean room standards. It is an
ideal complement to our capabilities in process and environmental monitoring
technology and aligns with our business strategy to be a total solutions
provider for the biotech and pharmaceutical industry."

                                    - ENDS -

For further information, please contact:

Biotrace International
Ian Johnson, Chief Executive Officer         Tel : +44 (0) 1656 641 400


Pall Corporation
Ken Frank, Corporate Vice President          Tel: +44 (0) 23 9230 2265


Buchanan Communications
Tim Anderson / James Strong                  Tel: +44 (0)20 7466 5000






Notes to editors:

Biotrace International Plc is a leading manufacturer and supplier of industrial
microbiology and life science products. The Company is organised into three
business segments: Industrial, Life Sciences and Defence. The Group's
proprietary technologies are used by most of the world's leading food and
beverage manufacturers who rely on Biotrace products as an essential part of
their quality control procedures. Industrial customers also include
pharmaceutical industries, personal care product manufacturers and environmental
water markets. The Life Sciences business manufactures highly specialised
workstations for hospital microbiology laboratories and medical research
organisations. The Defence segment provides systems and consumables for the
rapid detection of biological weapons.

Formed in 1988 and floated on the London Stock Exchange in 1993, Biotrace had
total revenues of #27 million in 2004. The Company is headquartered in Bridgend,
UK with manufacturing and sales operations worldwide. Visit Biotrace at
www.biotrace.com

Pall Corporation is the global leader in the rapidly growing field of
filtration, separations and purification. Pall's business is organised around
two broad markets: Life Sciences and Industrial. The Company provides
leading-edge products to meet the demanding needs of customers in biotechnology,
pharmaceuticals, transfusion medicines, semiconductors, water purification,
aerospace and broad industrial markets. Total revenues for fiscal 2005 were $1.9
billion. The Company headquarters are in East Hills, New York with extensive
operations throughout the world. Visit Pall at www.pall.com




                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
MSCDXLFFQFBLBBV

Bank Irel13.375 (LSE:BOI)
Gráfico Histórico do Ativo
De Jun 2024 até Jul 2024

Bank Irel13.375 (LSE:BOI)
Gráfico Histórico do Ativo
De Jul 2023 até Jul 2024